Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis

Karimi, Farzaneh; Azadbakht, Omid; Veisi, Ali; Sabaghan, Mohamad; Owjfard, Maryam; Kharazinejad, Ebrahim; Dinarvand, Negar

doi:10.1007/s12032-023-02128-0

Cited by 5 publications

(3 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is also a need for improvement in the precision and accuracy of detecting biomarkers in bodily fluids, which may be present at very low concentrations. Moreover, the technique is not entirely validated in the clinical spectrum, and reproducibility issues are present due to the use of multiple assays[ 51 , 52 ]. Two main groups of components can be tested.…”

Section: Modern Cancer Detection Methodsmentioning

confidence: 99%

Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods

Gromek,

Senkowska,

Płuciennik

et al. 2024

World J Methodol

View full text Add to dashboard Cite

In accordance with the World Health Organization data, cancer remains at the forefront of fatal diseases. An upward trend in cancer incidence and mortality has been observed globally, emphasizing that efforts in developing detection and treatment methods should continue. The diagnostic path typically begins with learning the medical history of a patient; this is followed by basic blood tests and imaging tests to indicate where cancer may be located to schedule a needle biopsy. Prompt initiation of diagnosis is crucial since delayed cancer detection entails higher costs of treatment and hospitalization. Thus, there is a need for novel cancer detection methods such as liquid biopsy, elastography, synthetic biosensors, fluorescence imaging, and reflectance confocal microscopy. Conventional therapeutic methods, although still common in clinical practice, pose many limitations and are unsatisfactory. Nowadays, there is a dynamic advancement of clinical research and the development of more precise and effective methods such as oncolytic virotherapy, exosome-based therapy, nanotechnology, dendritic cells, chimeric antigen receptors, immune checkpoint inhibitors, natural product-based therapy, tumor-treating fields, and photodynamic therapy. The present paper compares available data on conventional and modern methods of cancer detection and therapy to facilitate an understanding of this rapidly advancing field and its future directions. As evidenced, modern methods are not without drawbacks; there is still a need to develop new detection strategies and therapeutic approaches to improve sensitivity, specificity, safety, and efficacy. Nevertheless, an appropriate route has been taken, as confirmed by the approval of some modern methods by the Food and Drug Administration.

show abstract

Section: Modern Cancer Detection Methodsmentioning

confidence: 99%

Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods

Gromek,

Senkowska,

Płuciennik

et al. 2024

World J Methodol

View full text Add to dashboard Cite

show abstract

“…Furthermore, other recent studies have identified additional genetic alterations that contribute to platinum resistance in OC, such as mutations in RAD51C and RAD51D , which further complicate the treatment landscape [ 55 , 56 ]. Additionally, the high degree of genomic instability in OC can correlate with tumor heterogeneity, as demonstrated by Bashashati and colleagues [ 57 ], revealing distinct genetic profiles among tumor subclones that may respond differently to the therapy In line with this, researchers start to explored the implications of intratumor heterogeneity in OC prognosis, emphasizing the need for personalized treatment approaches [ 58 ]. Liquid biopsy technologies offer dynamic and precise monitoring of these genetic variations, aiding in the assessment of treatment response and disease progression [ 58 – 60 ].…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, the high degree of genomic instability in OC can correlate with tumor heterogeneity, as demonstrated by Bashashati and colleagues [ 57 ], revealing distinct genetic profiles among tumor subclones that may respond differently to the therapy In line with this, researchers start to explored the implications of intratumor heterogeneity in OC prognosis, emphasizing the need for personalized treatment approaches [ 58 ]. Liquid biopsy technologies offer dynamic and precise monitoring of these genetic variations, aiding in the assessment of treatment response and disease progression [ 58 – 60 ]. The genomic instability of both OC and PC has also opened new avenues for targeted therapy.…”

Section: Introductionmentioning

confidence: 99%

Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients

De Lazzari,

Opattova,

Arena

2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Over the last few decades, the incidence of urogenital cancers has exhibited diverse trends influenced by screening programs and geographical variations. Among women, there has been a consistent or even increased occurrence of endometrial and ovarian cancers; conversely, prostate cancer remains one of the most diagnosed malignancies, with a rise in reported cases, partly due to enhanced and improved screening efforts.Simultaneously, the landscape of cancer therapeutics has undergone a remarkable evolution, encompassing the introduction of targeted therapies and significant advancements in traditional chemotherapy. Modern targeted treatments aim to selectively address the molecular aberrations driving cancer, minimizing adverse effects on normal cells. However, traditional chemotherapy retains its crucial role, offering a broad-spectrum approach that, despite its wider range of side effects, remains indispensable in the treatment of various cancers, often working synergistically with targeted therapies to enhance overall efficacy.For urogenital cancers, especially ovarian and prostate cancers, DNA damage response inhibitors, such as PARP inhibitors, have emerged as promising therapeutic avenues. In BRCA-mutated ovarian cancer, PARP inhibitors like olaparib and niraparib have demonstrated efficacy, leading to their approval for specific indications. Similarly, patients with DNA damage response mutations have shown sensitivity to these agents in prostate cancer, heralding a new frontier in disease management. Furthermore, the progression of ovarian and prostate cancer is intricately linked to hormonal regulation. Ovarian cancer development has also been associated with prolonged exposure to estrogen, while testosterone and its metabolite dihydrotestosterone, can fuel the growth of prostate cancer cells. Thus, understanding the interplay between hormones, DNA damage and repair mechanisms can hold promise for exploring novel targeted therapies for ovarian and prostate tumors.In addition, it is of primary importance the use of preclinical models that mirror as close as possible the biological and genetic features of patients’ tumors in order to effectively translate novel therapeutic findings “from the bench to the bedside”.In summary, the complex landscape of urogenital cancers underscores the need for innovative approaches. Targeted therapy tailored to DNA repair mechanisms and hormone regulation might offer promising avenues for improving the management and outcomes for patients affected by ovarian and prostate cancers.

show abstract

The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications

Barbosa,

Filho

2024

Metabolomics

View full text Add to dashboard Cite

Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis

Cited by 5 publications

References 136 publications

Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods

Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods

Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients

The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications

Contact Info

Product

Resources

About